Open AccessPD‐1/PD‐L1, PD‐1/PD‐L2, and other co‐inhibitory signaling pathways in transplantation
Author(s) -
Del Rio MariaLuisa,
Buhler Leo,
Gibbons Carrie,
Tian Jiong,
RodriguezBarbosa JoseIgnacio
Publication year - 2008
Publication title -
transplant international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.998
H-Index - 82
eISSN - 1432-2277
pISSN - 0934-0874
DOI - 10.1111/j.1432-2277.2008.00726.x
Subject(s) - btla , immunosuppression , medicine , monoclonal antibody , transplantation , inhibitory postsynaptic potential , blockade , signal transduction , immunology , co stimulation , receptor , t cell , transplant rejection , cancer research , immune system , microbiology and biotechnology , antibody , biology , cd28
Summary Transplantation of cells, tissues and vascularized solid organs is a successful therapeutic intervention for many end‐stage chronic diseases. The combination of co‐stimulatory blockade with the delivery of negative signals to T cells through co‐inhibitory receptors would provide a robust approach to modulating T‐cell receptor signaling and improving alloantigen‐specific control of transplant rejection. This approach based on fundamental knowledge of APC/T‐cell interactions may complement conventional therapies in the near future to reinforce long‐term allograft survival, and permit minimal immunosuppression. The focus of this review was primarily on two major co‐inhibitory signaling pathways, namely PD‐1/PD‐L1/PD‐L2 and BTLA/CD160/HVEM/LIGHT that have been thoroughly characterized in murine models of transplantation using genetically modified mice, specific monoclonal antibodies and fusion proteins.